MajorDirect oral anticoagulants (factor Xa inhibitors)×Antiretroviral, HIV protease inhibitor
Updated · Methodology
Mechanism
CYP3A4/5 is the main enzyme that metabolises apixaban in the liver, and apixaban is also a substrate of the transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) (apixaban summary of product characteristics, SmPC, European Medicines Agency, EMA, section 5.2). Atazanavir inhibits CYP3A4, and its effect on P-gp is unknown and cannot be ruled out (atazanavir SmPC, EMA, section 4.5). Ritonavir, which is added to atazanavir to raise its levels, inhibits CYP3A4 more strongly than atazanavir and strongly inhibits P-gp. In the fixed-dose atazanavir/cobicistat tablet, cobicistat inhibits CYP3A4 and/or P-gp (atazanavir and atazanavir/cobicistat SmPCs, EMA, sections 4.2 and 4.5). Apixaban levels may therefore rise, and with them the risk of bleeding (atazanavir and atazanavir/cobicistat SmPCs, EMA, section 4.5). There are no pharmacokinetic data on this specific combination (European Heart Rhythm Association, EHRA, 2021 practical guide, Table 9). For comparison, ketoconazole, a strong CYP3A4 and P-gp inhibitor, doubled the apixaban area under the concentration–time curve (AUC) (apixaban SmPC, EMA, section 4.5).
Symptoms
The main risk is bleeding. Apixaban itself commonly causes bleeding, bruising, nosebleeds and haematomas, and major gastrointestinal and intraocular bleeding also occurs (apixaban summary of product characteristics, SmPC, European Medicines Agency, EMA, section 4.8). Severe bleeding can be fatal (apixaban label, US Food and Drug Administration, FDA, section 5.2). In people with haemophilia A and B treated with protease inhibitors, increased bleeding has been reported, including spontaneous skin haematomas and haemarthrosis. A causal link has been proposed, although the mechanism is unknown (atazanavir SmPC, EMA, section 4.4).
Management
The combination is not recommended. The EU atazanavir SmPC advises against apixaban with the atazanavir plus ritonavir regimen, and the SmPC of the fixed-dose atazanavir/cobicistat tablet advises against apixaban with that tablet (atazanavir and atazanavir/cobicistat SmPCs, European Medicines Agency, EMA, section 4.5). The apixaban SmPC also advises against apixaban in people on systemic treatment with strong inhibitors of CYP3A4 and P-glycoprotein (P-gp). Among the examples, it names human immunodeficiency virus (HIV) protease inhibitors such as ritonavir (apixaban SmPC, EMA, sections 4.4 and 4.5). The standard regimen in Europe is atazanavir with ritonavir. Ritonavir may be withdrawn only under restricted conditions, and then the possibility that atazanavir without ritonavir changes apixaban levels is taken into account (atazanavir SmPC, EMA, sections 4.4 and 4.5). The 2021 practical guide of the European Heart Rhythm Association (EHRA) marks apixaban with HIV protease inhibitors in red, which means contraindicated or not advisable because of increased plasma levels. For atazanavir alone, the guide suggests considering avoiding the combination. With ritonavir or cobicistat, it considers direct oral anticoagulants not advisable (EHRA 2021, Tables 5 and 9). For the regimen with ritonavir, the US atazanavir label refers to the apixaban dosing rules for strong CYP3A4 and P-gp inhibitors. A dose of 5 or 10 mg twice daily is reduced by 50%, and in people already taking 2.5 mg twice daily the combination is avoided (atazanavir and apixaban labels, US Food and Drug Administration, FDA, sections 2.6, 7.1 and 7.3). For atazanavir without ritonavir, the US label recommends close monitoring (atazanavir FDA label, section 7.3). If apixaban and atazanavir are nevertheless taken together, watch closely for signs of bleeding, and stop apixaban if severe bleeding occurs. For adults, a specific reversal agent for apixaban, andexanet alfa, is available (apixaban SmPC, EMA, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica de Eliquis 5 mg comprimidos recubiertos con película (apixabán) (2026)– AEMPS, CIMA (texto EMA), nº registro 111691009, secciones 4.4 y 4.5
- FDA: Eliquis (apixaban) prescribing information (2025)– FDA, DailyMed, Eliquis, E.R. Squibb & Sons, setid e9481622-7cc6-418a-acb6-c5450daae9b0, revisión 04/2025, secciones 4 y 7.1
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6
- FDA: Reyataz (atazanavir) prescribing information (2024)– DailyMed setid 165cff62-b284-4a27-a65d-9ec8a5bfcdd8, revisión 12/2024, secciones 4 y 7.3
- EMA: Ficha técnica: Atazanavir/cobicistat (EU/1/15/1025), sección 4.5 (2026)– EMA, Evotaz 300 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, secciones 4.3 y 4.5
- EMA: Ficha técnica: Atazanavir, Reyataz (EU/1/03/267), sección 4.3 (2026)– EMA, Reyataz 300 mg cápsulas (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 03267008, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 y 4.5